Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Masato KarayamaNaoki InuiYusuke InoueKatsuhiro YoshimuraKazutaka MoriHironao HozumiYuzo SuzukiKazuki FuruhashiTomoyuki FujisawaNoriyuki EnomotoYutaro NakamuraKazuhiro AsadaTomohiro UtoMasato FujiiTakashi MatsuiShun MatsuuraDai HashimotoMikio ToyoshimaHideki KusagayaHiroyuki MatsudaNao InamiYusuke KaidaMitsuru NiwaYasuhiro ItoTakafumi SudaPublished in: Cancer immunology, immunotherapy : CII (2021)
Based on the association of prolonged survival in patients with increased serum cholesterol and long-chain fatty acid levels, serum lipid levels may be useful for predicting the efficacy of immune checkpoint inhibitor therapy.
Keyphrases